Patents
Literature
4 results about "Toll-like receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate immune system. They are single, membrane-spanning, non-catalytic receptors usually expressed on sentinel cells such as macrophages and dendritic cells, that recognize structurally conserved molecules derived from microbes. Once these microbes have breached physical barriers such as the skin or intestinal tract mucosa, they are recognized by TLRs, which activate immune cell responses. The TLRs include TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, and TLR13, though the last three are not found in humans.
Cancer vaccine and method of use thereof
PCT designated stageWO2026076308A1Organic active ingredientsMammal material medical ingredientsDendritic cellCancer cell
Disclosed is a cancer vaccine that contains dendritic cells. The dendritic cells are prepared by: culturing immature dendritic cells to maturation; co-culturing the matured dendritic cells with attenuated cancer cells, Mannan – BAM (Mannan, a yeast-derived polysaccharide, and BAM, a Biocompatible Anchor for Cell Membrane), and TLR (Toll like receptor) agonists; and optionally sorting the dendritic cells from the co-cultured attenuated cancer cells.
Owner:NE1 INC +1
Compounds for use in the treatment of heart failure with preserved ejection fraction (HFPEF), through targeting of s100a9 and corresponding dimer partner and receptors
The present invention refers to inhibitors of the S100 calcium- binding protein A9 (S100A9) / S100A8 – Toll Like Receptor 4(TLR4) dimer-receptor axis for use in the treatment of Heart Failure with preserved Ejection Fraction (HFpEF). The present invention further refers to pharmaceutical formulations comprising the said inhibitors. The present invention's use of compounds and pharmaceutical formulations may be advantageously employed in HFpEF by attenuating the deleterious effect on endothelial function and prevention of inflammation, production of reactive oxygen species, apoptosis, senescence and pro-fibrotic phenotype.
Owner:I3S - INST OF HEALTH RES & INNOVATION ASSOC +2
Activated stem cell derived products for stimulation of skin regeneration
PCT designated stageWO2026064321A1Peptide/protein ingredientsAntipyreticToll-like receptorCollagenan
Disclosed herein are means, methods, and compositions of matter useful for stimulation of elastin / collagen production and suppression of matrix metalloprotease activity. The disclosure further provides compositionally useful preparations derived from regenerative cells that have been manipulated for optimum growth factor and anti-aging properties. In one embodiment cellular mixtures derived from regenerative cells contacted with activating signals. Said activating signals include stimulation of toll like receptors and other "danger" sensing molecules. In one embodiment regenerative factors are harvested from stem cells and compounded into composition preparations.
Owner:ROBLES BIOCEUTICS LLC
Endothelial stimulation of hepatic regeneration
Therapeutic formulations and protocols for enhancement of hepatic regeneration, reduction / reversion of liver failure, and restoration of hepatic characteristics of young liver including augmented production of digestive enzymes, production of complement, and detoxificiation. In one embodiment endothelial progenitor cells are cultured in vitro under conditions capable of stimulating enhanced production of microvesicles such as exosomes and / or regenerative factors. Endothelial cells can be activated to produce regenerative factors and / or exosomes by exposure to toll like receptor agonists. Endothelial cells may be autologous, allogeneic or xenogeneic to the recipient.
Owner:IMMORTA BIO INC